BRCA1 and ovarian cancer: Therefore, PARP inhibitors may not be limited to BRCA1/2 mutations in ovarian cancer and may even be extended to sporadic ovarian cancer patients with homologous recombination defects (HRD) or BRCA1/2 gene epigenetic abnormalities.